Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707057 | 0.86 | HTR2C (0.63) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL6709455 | 0.81 | HTR2C (0.59) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL15959896 | 0.80 | SLC6A2 (0.47) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Nitrogen SCHEMBL6015229 | 0.79 | SLC6A2 (0.47) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL4895882 | 0.78 | HTR2C (0.55) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL22542016 | 0.77 | SLC6A2 (0.63) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL5937352 | 0.77 | HTR6 (0.48) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL6709469 | 0.77 | SLC6A2 (0.59) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23712339 | 0.76 | HTR2C (0.61) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL6036481 | 0.76 | HTR2C (0.66) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765959-B2 | Piperidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765959-B2 | Piperidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20130165444-A1 | Piperidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| US-20130165444-A1 | Piperidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165444-A1 | Piperidine Derivatives | PPARD, FABP4, PLIN5 | HTR2C 1569/4885SLC6A2 4373/4885SLC6A4 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.